An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
VanBlargan et al.,
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal..,
bioRxiv, doi:10.1101/2021.12.15.472828 (Preprint) (In Vitro)
In vitro study (Vero-TMPRSS2 and Vero-hACE2-TMPRSS2) showing complete loss of inhibitory activity for B.1.1.529 omicron with LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59, ~12-fold decrease for COV2-2196/COV2-2130, and minimal change for S309.
Efficacy is highly variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, VanBlargan].4 In Vitro studies support the efficacy of bamlanivimab/etesevimab
[Liu (B), Sheward (B), VanBlargan (B), Zhou].
VanBlargan et al., 17 Dec 2021, preprint, 10 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Abstract: bioRxiv preprint doi: https://doi.org/10.1101/2021.12.15.472828; this version posted December 17, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.
1
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by
2
several therapeutic monoclonal antibodies
3
4
Laura A. VanBlargan1, John M. Errico2, Peter J. Halfmann3, Seth J. Zost4,5, James E. Crowe
5
Jr.4,5,6, Lisa A. Purcell7, Yoshihiro Kawaoka3,8,9, Davide Corti10, Daved H. Fremont2,11,12, and
6
Michael S. Diamond1,2,11,13,14
7
8
1
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
9
2
Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO,
10
USA
11
3
12
University of Wisconsin-Madison, Madison, WI, USA.
13
4
Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA
14
5
Department of Pediatrics Vanderbilt University Medical Center, Nashville, TN, USA
15
6
Department of Pathology, and Microbiology and Immunology, Vanderbilt University Medical Center,
16
Nashville, TN, USA
17
7
Vir Biotechnology, St Louis, MO, USA.
18
8
Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science,
19
University of Tokyo, 108-8639 Tokyo, Japan.
20
9
21
Research Institute, Tokyo 162-8655, Japan.
22
10
Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
23
11
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO.
24
12
Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St.
25
Louis, MO.
26
13
27
Washington University School of Medicine, Saint Louis, MO.
28
14
29
Saint Louis, MO.
30
Corresponding author: Michael S. Diamond, M.D., Ph.D., mdiamond@wustl.edu
Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine,
The Research Center for Global Viral Diseases, National Center for Global Health and Medicine
Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs,
Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine,
1
bioRxiv preprint doi: https://doi.org/10.1101/2021.12.15.472828; this version posted December 17, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC-ND 4.0 International license.
31
ABSTRACT
32
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the
33
global COVID-19 pandemic resulting in millions of deaths worldwide. Despite the
34
development and deployment of highly effective antibody and vaccine countermeasures,
35
rapidly-spreading SARS-CoV-2 variants with mutations at key antigenic sites in the spike
36
protein jeopardize their efficacy. Indeed, the recent emergence of the highly-transmissible
37
B.1.1.529 Omicron variant is especially concerning because of the number of mutations,
38
deletions, and insertions in the spike protein. Here, using a panel of anti-receptor binding
39
domain (RBD) monoclonal antibodies (mAbs) corresponding to those with emergency..
vanblargan
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit